Tag Archives: Daniel O’Day

Roche to fully acquire Ignyta for US$ 1.7 billion in an all-cash transaction

Roche to acquire Ignyta for US$ 27.00 per share Ignyta’s investigational medicine entrectinib, a selective CNS-active tyrosine-kinase inhibitor being developed for tumours that harbor ROS1 or NTRK fusions, to expand Roche’s portfolio of oncology medicines BASEL, 27-Dec-2017 — /EuropaWire/ — … Read the full press release

Roche to acquire up to 56.3% interest in Foundation Medicine, Inc. on a fully diluted basis through a tender and acquisition of newly issued shares

BASEL, 12-1-2015 — /EuropaWire/ — Collaboration leverages both companies’ strengths to advance the progress of personalized treatments for patients with cancer Roche to acquire a majority interest in Foundation Medicine (FMI) of up to 56.3% on a fully diluted basis … Read the full press release

Roche to invest CHF 800 million to increase production capabilities for its biologic medicines

Investment to help meet rising demand for licensed biologics and expected pipeline growth Basel, Switzerland, 16-10-2013 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced plans to invest 800 million Swiss francs within its global manufacturing network to increase production … Read the full press release